Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UNIPROT:Q06643 (non-Hodgkin's lymphoma)
 11,307 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Three cases of acute renal failure (ARF) requiring renal replacement therapy (RRT) in the course of neoplastic disease were presented. 7.5-yr-old girl admitted with postrenal failure during palliative radiotherapy had metastases in retroperitoneal space. Improvement followed percutaneous placement of nephrostomy catheters. 16-yr-old boy with acute myeloid leukemia was effectively treated with hemodialysis for prerenal and renal ARF mediated by vasomotor, infectious and toxic factors. In 11-yr-old boy ARF was the first clinical presentation of non-Hodgkin's lymphoma. Chemotherapy brought restoration of renal function. As a conclusion we emphasize complex etiology of ARF in such patients as well as the necessity of early introduction of RRT and thorough diagnosis and proper management of the causes of impaired renal function.
Pol Merkur Lekarski 2002 Dec
PMID:[Acute renal failure as complication of neoplastic disease in children]. 1266 50

A rare case of primary non-Hodgkin's lymphoma (NHL) of the jaw is reported. Precise diagnosis of such primary manifestation of NHL may pose a diagnostic problem due to unspecific clinical and radiological findings as well as difficult interpretation of biopsy specimens. The prognosis is related to the clinical stage, tumour aggressiveness and response to treatment.
Pol Merkur Lekarski 2003 Mar
PMID:[Primary location on non-Hodgkin's lymphoma in the jaw: a case study]. 1291 6

We analysed the outcome of 200 patients, aged 38 (13-72) years, with aggressive non-Hodgkin's lymphoma (NHL) treated with high-dose chemotherapy followed by autologous haematopoietic stem cell transplantation (autoHSCT) in ten oncohaematological centres belonging to Polish Lymphoma Research Group (PLRG). The source of stem cells for transplantation was peripheral blood (autoPBSCT, n = 153), bone marrow (autoBMT, n = 40) or both blood and bone marrow (n = 7). The probability of overall survival (OS) and progression-free survival at 10 years was 51% (+/- 7%). The transplant-related mortality rate equalled 7%. In multivariate analysis, the only factor influencing independently the probability of OS was disease status at transplantation (p < 0.00001). The outcome of patients transplanted in first or subsequent complete remission or first partial remission (PR) was significantly better compared with subjects given autoHSCT in PR 2 or those with primary or secondary refractoriness. Regarding histological subtypes, the highest OS rate (87%) was observed for anaplastic large T cell lymphoma. The outcome after autoBMT was better compared with autoPBSCT (OS probability: 67% vs. 43%), although the difference did not reach statistical significance. We conclude that high-dose therapy followed by autoHSCT is an effective option for high-risk aggressive NHL. Remission status is a major factor determining long-term outcome. This should be taken into account when referring patients for autoHSCT.
Pol Arch Med Wewn 2003 Aug
PMID:[Autologous hematopoietic stem cell transplantation for the treatment of aggressive non-Hodgkin's lymphoma. The experience of Polish lymphoma research group]. 1468 25

The aim of the investigation was the assessment of the role of routine cytology and clonality evaluation using PCR in differential diagnosis of lymphoproliferative diseases of the orbit and eye adnexa. The investigations were carried out in cellular material collected via fine needle aspiration biopsy (FNAB) from 29 patients aged 31-82 years, including 17 women and 12 men. Apart from routine cytology, molecular-genetic studies were performed employing the PCR technique. In 21 cases histopathology was performed. In 2 patients, despite several attempts, FNAB failed to provide any diagnostic material for routine cytology. Based on cytology, non-Hodgkin's lymphoma was diagnosed in 11 patients and suspected in three. In 13 patients no firm diagnosis was possible based on cytological smears. The employment of PCR allowed for rendering the diagnosis more precise in 13 cases, confirming it in 13 patients, while in 3 cases the results of the above tests did not affect the final diagnosis. Clonality studies by PCR may be performed in material obtained through FNAB. Clonality assessment by PCR technique is very useful in differential diagnosis of lymphoproliferative disordes.
Pol J Pathol 2004
PMID:Fine needle aspiration biopsy and molecular analysis in differential diagnosis of lymphoproliferative diseases of the orbit and eye adnexa. 1546 7

Pathologic rupture of the spleen is an uncommon but life-threatening complication of some malignant diseases. This paper presents a case of splenic rupture which occurred in a man with non-Hodgkin's lymphoma. We briefly discuss etiology, pathophysiology, symptoms and treatment of this complication.
Pol Merkur Lekarski 2004 Nov
PMID:[Pathologic splenic rupture in the course of non-Hodgkin's lymphoma]. 1575 41

A case of tracheobronchiale stenosis due to non-Hodgkin's lymphoma (mantle cell lymphoma) of the exceptionaly rare location, in 75 old woman is described. After the restoration of airways patency and stent implantation dyspnea was removed.
Otolaryngol Pol 2007
PMID:[Tracheal stenosis due to non-Hodgkin's lymphoma of the exceptionaly rare location]. 1854 47

Rituximab is a chimeric human-mouse monoclonal antibody, which binds to the CD20 antigen on B lymphocytes and causes depletion of CD20+ cells in the mechanism of complement-dependent and independent cytolysis, cell cytotoxicity and antibody-dependent mechanism and apoptosis. Rituximab is currently registered for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia and rheumatoid arthritis. Rituximab also demonstrated efficacy in a number of other autoimmune diseases, including systemic lupus erythematosus. In patients with systemic lupus erythematosus rituximab decreases the number of autoreactive VH4.34 B cells, what contributes to sustaining B cell homeostasis and immune tolerance. A decrease in levels of circulating anti-dsDNA antibodies and an increase of C3 concentration is observed parallel to clinical improvement. Diagnostic procedures performed before initiation of rituximab therapy and during treatment include basic laboratory tests as well as exclusion of heart insufficiency and infections.
Pol Merkur Lekarski 2010 Aug
PMID:[Rituximab in systemic lupus erythematosus. Part I. Theoretical basis]. 2084 29

Rituximab is a chimeric human-mouse monoclonal antibody, which binds to the CD20 antigen on B lymphocytes and causes depletion of CD20+ cells. Rituximab is currently registered for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia and rheumatoid arthritis. Rituximab also demonstrated efficacy in a number of other autoimmune diseases, including systemic lupus erythematosus. Data available from over published 200 cases may indicate that 50-75% of patients with lupus achieve at least partial remission after rituximab therapy. This effect was not confirmed in a randomized, double-blind phase II/III clinical trial. However methodological inaccuracies which might have led to incorrect conclusions in this trial were pointed out. Further studies are needed to evaluate efficacy of rituximab in different clinical and immunological subtypes of systemic lupus erythematosus.
Pol Merkur Lekarski 2010 Aug
PMID:[Rituximab in systemic lupus erythematosus. Part II: review of clinical experience]. 2084 30

More than ten years ago we made first attempts at valuating a prognostic power of flow cytometric DNA measurement results for patients with non-Hodgkin's lymphoma. In multivariate overall survival analysis, S-phase fraction (SPF) showed to be the only independent prognostic factor within the group of patients with low grade lymphomas. In this paper, we have tried to check our previous results in a greater group of patients with longer follow-up, within the specific types of B-cell and T/NK-cell lymphomas verified and classified according to criteria of the WHO 2008 classification. The study was performed on the material obtained from biopsies (85% of lymph nodes) of 484 NHL patients. Patients were diagnosed from 1991 to 2007. The medium follow-up time for living patients was 69 months (range: 25-202 months). All specimens were verified histologically and immunohistochemically. Ploidy and SPF were determined by flow cytometry on fresh tissue obtained during the diagnostic procedure. The diagnostic importance of ploidy and SPF has been confirmed. Ploidy had no predictive or prognostic impact in any of the NHL types, whereas SPF was found to be an independent predictive or prognostic factor in B-CLL/SLL, DLBCL and ALCL.
Pol J Pathol 2012 Mar
PMID:Diagnostic, predictive and prognostic verification of DNA flow cytometric measurements performed at diagnosis for non-Hodgkin's lymphoma adult patients. 2253 2

Kikuchi-Fujimoto disease (KFD), also known as histiocytic necrotizing lymphadenitis, is a benign and self-limited disease, characterized typically by enlargement of regional lymph nodes accompanied by fever. KFD affects predominantly young adult females of Asian origin and is rarely seen in European countries, where it may cause diagnostic difficulties. Two cases of KFD in a 33 and 27-year-old woman with mild fever, malaise, lymphadenopathy initially misdiagnosed for indolent non-Hodgkin's lymphoma was presented. The definitive diagnosis was established on the basis of histopathological examination of totally excised cervical lymph nodes. The propriety diagnosis allowed us to avoid inappropriate chemotherapy. The disease course in our patient was uneventful during the 1.5 and 12-year follow-up period. The clinical presentations, complications as well as current concepts on pathogenesis, diagnosis and treatment of the Kikuchi-Fujimoto disease was briefly reviewed in this paper. The need of a long-term follow-up of patients with Kikuchi-Fujimoto disease was emphasized.
Otolaryngol Pol
PMID:Kikuchi-Fujimoto disease as a rare cause of lymphadenopathy--two cases report and review of current literature. 2337 56


<< Previous 1 2 3 4 Next >>